GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst

JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings GDRX following the company’s first-quarter earnings. Gill reaffirmed an Overweight rating on the stock and maintained her $7 price forecast.The company reported first-quarter 2025 revenue of$ 203 million (above the $202.21 million estimate), up 3% year-over-year. Adjusted EBITDA rose to$ 69.8 million, with margins improving to 34.4% from 31.7%. Net income came in at $11.1 million, reversing a$ 1 million loss in the prior year.Pharma ...